L Lashnews Medical aesthetics sourcing from China
News Sourcing Guide

【South Korea】Hugel Launches New HA Filler with Reduced Crosslinking Agent, Emphasizing Enhanced Safety

Editor’s Note

**Editor’s Note:** Hugel has launched TheCharm Signature, a new hyaluronic acid filler designed to improve safety by minimizing crosslinking agents. The product line includes four variants with diverse physical properties, aiming to strengthen the company’s market competitiveness.

New Product Launch

Hugel has launched ‘TheCharm Signature,’ a new hyaluronic acid (HA) filler that minimizes the use of crosslinking agents to enhance safety. (Photo: Hugel)

[Bizworld] Hugel has introduced a new HA filler product to strengthen its competitiveness.

Hugel announced on the 21st that it has launched ‘TheCharm Signature,’ which minimizes the use of crosslinking agents to enhance safety.

According to the company, TheCharm Signature consists of four products with a broad spectrum of physical properties, allowing medical professionals to choose based on the treatment area and purpose.

The product line is described as integrating the company’s R&D achievements.

Typically, HA fillers undergo a crosslinking process to maintain hyaluronic acid, which is easily broken down in the body, in a stable gel form.

For TheCharm Signature, the company explained that it applies the ‘MPC (Multi Purified Crosslinking) method,’ a proprietary technology of its affiliate ‘Across,’ which reduces the amount of crosslinking agent by over 50% compared to conventional manufacturing processes and maximizes crosslinking efficiency through a special process using high-concentration HA raw materials.

Additionally, the company stated that through a multi-purification process lasting about two weeks—longer than typical manufacturing processes—it significantly reduces residual crosslinking agent (BDDE) as well as micro-hydrolysis byproducts (BDPE) that can arise during the crosslinking stage.

“Hugel, which has built a solid position in the HA filler field through long-term R&D and accumulated technology, has now introduced a differentiated new product applying its proprietary MPC method,” said Jang Doo-hyun, CEO of Hugel. “We will continue to strengthen product competitiveness and safety, and further build trust with both medical professionals and consumers.”

[Bizworld = Reporter Kim Mi-jin / [email protected]]

Full article: View original |
⏰ Published on: July 21, 2026